FDA MoCRA Facility Registration Deadlines You Can't Miss in 2026

The FDA Modernization of Cosmetics Regulation Act (MoCRA) has been the law since December 2022, but 2026 is when the rubber meets the road. I have worked with contract manufacturers who assumed the extended enforcement timeline meant they could wait. They were wrong. The truth is, if you first registered your cosmetic facility in 2024 to meet FDA's initial deadline, your biennial renewal comes due in 2026. Miss it, and you are not just out of compliance—you are shut out of the US market. This article is for B2B suppliers in oral care, hair care, and personal care who manufacture or import into the United States. No filler. Just the timeline, the mechanics, and the mistakes that actually trigger FDA action.

What MoCRA Changed for Personal Care Suppliers Since December 2022

Before MoCRA, cosmetic facility registration was voluntary. The FDA could ask nicely. Companies could ignore them. That world is gone. FD&C Act section 607, added by MoCRA, now mandates that every facility that manufactures or processes cosmetic products for distribution in the United States must register with FDA. This is not a one-time filing. Registration must be renewed every two years under section 607(a)(2). Product listing is separate—required annually—and I will get to that distinction because conflating the two is the fastest way to mess this up. The December 2022 statutory framework gave FDA new authority: mandatory recalls, serious adverse event reporting (required within 15 business days), access to safety substantiation records, and the registration and listing infrastructure that makes enforcement possible. For oral care suppliers manufacturing toothpaste or mouthwash, hair care formulators producing conditioners and styling products, and personal care contract manufacturers running multiple lines—the same rules apply. There are limited exemptions. Small businesses under certain revenue thresholds may qualify for exemptions from some requirements such as GMP, registration, and product listing, but facility registration itself is broadly required for most manufacturers and processors. FDA exercised enforcement discretion through 2023 and into 2024, with the agency stating it did not intend to enforce registration and listing requirements until July 1, 2024. That grace period has a hard stop. The compliance policy framework FDA established makes clear that registration and listing are operational prerequisites, not optional steps. Here is the thing: the industry treated 2023–2024 as a soft opening. 2026 is opening night. No dress rehearsal.

FDA MoCRA Facility Registration vs. Product Listing: Key Differences Explained

I see this confused constantly, even by compliance officers who should know better. Let me be blunt about the distinction. Facility registration is about where. Product listing is about what. Under FD&C Act section 607(a), facility registration identifies the physical manufacturing or processing location. The owner or operator submits facility name, address, email, telephone, and operations details through FDA Cosmetics Direct. This registration is biennial—every two years from the initial registration date. FDA's portal guidance explicitly confirms: renewal dates are based on your initial registration date, not a universal calendar deadline. Product listing under section 607(c) is annual. Each cosmetic product—with its ingredient composition, responsible party contact, and associated facility registration number—must be listed. A single facility can have dozens or even hundreds of product listings. One registration, many listings. The practical implication? Your 2024 facility registration renewal hits in 2026. Your product listings from 2024 needed updating in 2025, and new listings from 2025 need updating again in 2026. Different cycles. Different deadlines. Different consequences for non-compliance. For B2B suppliers running private label programs, this creates operational complexity. Your FDA MoCRA facility registration covers your manufacturing site. But each client's product line requires separate listing, with the responsible person—typically the brand owner identified on the product label, not the contract facility—named. I have watched contract manufacturers get caught in the middle when brand owners fail to list products properly. The facility gets the FDA inquiry anyway. My read on enforcement priorities: facility registration is the easier enforcement target. It is binary—registered or not. Product listing has more variables, more parties involved, more opportunity for FDA to issue guidance before penalties. But neither is optional.

The 2026 Enforcement Calendar: Critical Dates and Penalty Risks

Let me give you the calendar that matters. If you registered your facility in 2024 to comply with FDA's initial MoCRA rollout, your biennial renewal is due in 2026. The exact month depends on when you first registered. FDA's portal guidance is explicit: renewal is every two years from the date of initial registration. There is no blanket "all renewals due December 31" deadline. This requires active calendar management rather than a single industry-wide rush. But here is what creates the 2026 crunch: many facilities registered in mid-to-late 2024 as the enforcement discretion period narrowed toward the July 1, 2024 date. That clusters renewals in the second and third quarters of 2026. Annual product listing updates operate on their own cycle. If you listed products in 2024, updates were due in 2025. New 2025 listings need 2026 updates. FDA's compliance policy framework indicates that current, accurate listing is expected as a condition of compliance. Penalty risks under MoCRA are substantial. While FDA has emphasized education-first enforcement for initial registration, the statute provides for misbranding and adulteration designations for products from unregistered facilities. Practically, this means:

Import detention at US ports for foreign facilities without valid registration
Refusal of admission for cosmetic products from unregistered manufacturers
Warning letters escalating to injunction or seizure for persistent non-compliance
Commercial consequences: retailers and brand partners increasingly verify registration status before contracting

The industry gets this wrong by focusing only on FDA's visible enforcement. The bigger risk in 2026 is supply chain verification. Major retailers and brand holders are building registration checks into their vendor onboarding. Unregistered? Unapproved. No purchase order. If your company supplies oral care products to US retailers, this commercial reality may bite harder than any FDA warning letter. I am not predicting FDA will swarm every late renewal on day one. I am saying the statutory framework is in place, the portal is operational, and the enforcement discretion period is over. The businesses that treated 2024 registration as a checkbox exercise will face 2026 renewal as a strategic vulnerability.

Step-by-Step: How to Complete FDA MoCRA Facility Registration on Cosmetics Direct

FDA Cosmetics Direct is the only authorized portal. No third-party shortcuts. No paper alternatives for initial registration. Step one: establish an account. You need a verified email and organizational identification. The system assigns a facility registration number upon completion—not before, not provisional. Step two: enter facility information. This includes legal business name, physical address (no PO boxes), mailing address if different, contact person with direct phone and email, and operational scope. Be precise about whether you manufacture, process, or both. Contract manufacturers: specify that you produce for multiple responsible persons. This affects how FDA structures inquiries. Step three: designate a US agent if foreign. Foreign facilities must identify a US-based agent for FDA communication. This is not a formality. FDA will contact this person for inspections, sample collections, and emergency notices. Choose someone responsive, not just available. Step four: submit and confirm. The system generates a confirmation with registration number and date. Save this. The renewal date is calculated from this exact date. For biennial renewal, FDA provides an abbreviated renewal pathway if no information has changed. Do not assume nothing changed. Verify. Address changes, ownership transfers, operational additions—all require updated registration, not just renewal. The portal's informational materials walk through this process, but I have seen facilities miss acquisitions and later wonder why their registration appears invalid. Payment: currently, there is no FDA fee for cosmetic facility registration. This differs from drug or device establishment registration. But budget for compliance infrastructure—personnel time, system maintenance, legal review of changes. One practical note: the portal can experience volume surges near perceived deadlines. Submit early. Your renewal window opens before the exact two-year anniversary. Use it.

Product Listing Requirements for Oral Care and Hair Care Lines

Oral care and hair care products are cosmetics under FDA jurisdiction unless they make drug claims. Toothpaste with fluoride? Drug. Toothpaste without fluoride, positioned for cleaning and freshening? Cosmetic. Anti-dandruff shampoo? Drug. Standard cleansing shampoo? Cosmetic. The boundary matters because drug products face entirely different registration requirements under FD&C Act sections 510 and 760. For cosmetic oral care and hair care lines, product listing requires:

Product name and category
Ingredient composition, including fragrances and colors
Responsible person name and contact information
Facility registration number where the product is manufactured

Annual updates are mandatory for any changes. New product launches require listing before commercial distribution. Discontinued products should be marked as such—FDA's system accommodates this, and maintaining active listings for defunct products creates confusion during inspections. The B2B complexity: who lists? If you are a contract manufacturer producing a brand owner's formula, the brand owner is typically the responsible person and must list the product. But your facility registration number must be included. This creates interdependency that many supplier agreements do not adequately address. I recommend explicit contractual language: brand owner responsibility for timely listing, facility cooperation in providing registration numbers and manufacturing details, mutual notification of FDA inquiries. I have seen relationships fracture when warning letters arrive and neither party accepted compliance responsibility. For hair care specifically, product categories span shampoos, conditioners, styling products, colorants, and treatments. Each requires separate listing if marketed under distinct names, even with similar formulation bases. Oral care spans toothpastes, mouthwashes, breath fresheners, and whitening products (cosmetic-claim only). The listing burden scales with SKU proliferation.

How MoCRA Affects Foreign Suppliers Exporting to the United States

Foreign facilities face amplified requirements. The US agent designation is non-negotiable. FDA will not communicate directly with overseas addresses for regulatory matters. Foreign facilities must register before products enter the United States. Port detention for unregistered facilities can be immediate. Unlike domestic enforcement where FDA may issue notice first, CBP and FDA coordination at ports means physical hold can occur without advance warning. The biennial renewal applies equally. A facility in Germany, South Korea, or Mexico that registered in 2024 renews in 2026. No geographic exemption. Product listing for imported products follows the same responsible person framework, but the responsible person must be a US-domiciled entity. Foreign brand owners cannot serve as the responsible person under MoCRA. This typically requires establishing a US subsidiary, contracting with a US distributor, or engaging a regulatory representative. Each structure has implications for liability, record access, and adverse event reporting. FDA's compliance policy materials emphasize that foreign suppliers are expected to maintain equivalent documentation and safety substantiation as domestic manufacturers. Translation requirements, record retention, and inspection accessibility—including potential FDA foreign inspections under MoCRA authority—all factor into 2026 readiness. For European suppliers specifically: EU Cosmetics Regulation (EC) No 1223/2009 compliance does not map directly to MoCRA. The responsible person concept exists in both systems, but definitions, notification systems, and safety assessment requirements differ materially. Do not assume familiarity with EU compliance translates to FDA compliance efficiency.

Common FDA MoCRA Facility Registration Mistakes That Trigger Warning Letters

After reviewing FDA's compliance approach and industry reporting, here are the errors that actually generate enforcement action. Mistake one: confusing facility registration with product listing. I have covered this, but it bears repeating because it is the most common root cause of compliance gaps. Facilities think they are covered because they filed something. They filed the wrong thing, or filed one and not the other. Mistake two: failing to update registration after facility changes. New address after relocation? New ownership after acquisition? Added processing capabilities? These are not just renewal items—they require prompt registration updates. FDA's system flags discrepancies between registration data and inspection findings. Mistake three: letting the biennial renewal lapse. The two-year clock does not pause. There is no automatic reminder system that guarantees you will not miss your window. Build an internal compliance calendar. Assign ownership. Verify completion. Mistake four: designating an unresponsive US agent. For foreign facilities, a US agent who does not answer FDA communications is functionally the same as having no agent. FDA has flagged this pattern and treats it as a registration deficiency. Mistake five: assuming contract manufacturing shields you from responsibility. If you operate the facility, you register. Whether the brand owner, distributor, or end customer holds the marketing authorization is irrelevant to your facility registration obligation. Both the facility and the responsible person carry distinct duties. For companies managing personal care product lines, each of these mistakes compounds across product categories and client relationships. A single lapse can cascade into dozens of affected SKUs.

Building a 2026 MoCRA Compliance Calendar

Here is what a practical compliance calendar looks like for a B2B personal care supplier:

Q1 2026: Audit all facility registration dates. Identify which facilities hit their two-year anniversary in 2026. Begin renewal preparation for any registrations filed in Q1 2024.
Q2 2026: Submit renewals for mid-2024 registrations. Verify US agent information for foreign facilities. Confirm product listing updates for annual cycle.
Q3 2026: Process renewals for late-2024 registrations. Cross-reference product listings with active SKUs. Deactivate discontinued product listings.
Q4 2026: Year-end compliance audit. Document all registration and listing activity. Prepare for 2027 product listing annual updates.

The companies that survive MoCRA enforcement without disruption are the ones that treat registration and listing as ongoing operational functions, not annual fire drills. Build the system now. The 2026 deadlines are not theoretical—they are the direct consequence of decisions made in 2024.

References

Disclaimer

This article is for informational purposes only. LLRNCARE makes no representations or warranties about the completeness, accuracy, or reliability of the information. Any reliance is at your own risk. For professional dental advice, consult a qualified dental professional. For regulatory compliance, consult legal experts.